Frozen deglycerolyzed blood prevents transfusion-acquired cytomegalovirus infections in neonates

Frozen deglycerolyzed blood (FDB) was used for routine transfusions to 63 low birth weight newborns (less than or equal to 1500 g) over a 12-month period in an effort to decrease transfusion-acquired cytomegalovirus (CMV) infections. Nine of the 63 infants also received nonfrozen blood products (platelets, liquid blood). Seventy-two percent of the donor blood units were CMV-seropositive. Urine cultures and serum titers for anti-CMV antibody (immunoglobulins G and M) were obtained prior to the initial transfusion and sequentially throughout the study. No infant (0 of 54) who received only FDB acquired CMV, whereas 3 of 9 infants (33%) who received non-frozen blood and FDB acquired CMV, as evidenced by CMV viruria and/or a 4-fold rise in immunoglobulin G anti-CMV antibody titers. These results suggest that transfusions with frozen deglycerolyzed blood decrease the risk in low birth weight infants of acquiring CMV, regardless of the CMV serologic status of the donor.